Quartet Medicine - BH4

About Quartet Medicine

Quartet Medicine is a private, biotechnology company focused on discovering and developing novel treatments for chronic pain and inflammation. Human genetics and preclinical target validation data point to increased tetrahydrobiopterin (BH4) as a critical mediator of peripheral nerve dysfunction and immune cell regulation. Quartet is capitalizing on these insights by safely restoring BH4 homeostasis in neuronal and inflammatory cells.

Quartet was founded by scientists at Boston Children’s Hospital and École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland in conjunction with Atlas Venture. Quartet’s Series A investors include Atlas Venture, Novartis Venture Funds, Pfizer Venture Investments and Partners Innovation Fund. The company is based in Cambridge, Massachusetts and has research efforts underway with collaborators in the US, Europe and Asia.

Back: Mark Tebbe, Mark Versavel, Gerhard Koenig, Steven Sweeney, Ray Hurst

Front: Annika Malmberg, Darby Schmidt, Oanh Sam, Joanne Bryce